ºÚÁÏ³Ô¹Ï Signs Exclusive License with Propagenix to Commercialize EpiXâ„¢, an Innovation Empowering Epithelial Cell Biology and Cell Therapy
ºÚÁÏ³Ô¹Ï has signed an exclusive license with Propagenix of Rockville, MD to commercialize its patented EpiXâ„¢ technology, a novel and revolutionary cell culture medium that enables unprecedented expansion of tissue-resident epithelial stem cells without any genetic manipulation
09/20/2017
EpiXâ„¢ outperforms current state-of- the-art cell culture systems, which typically yield fewer than 20 population doublings before the cells senesce. Epithelial stem cells derived from many tissue types can be propagated more than a trillion-fold in Epixâ„¢. The expanded cells are genetically stable, are not tumorigenic, and can be readily differentiated into tissue-specific phenotypes even after extensive expansion.
Dr. Allen Eaves, ºÚÁϳԹÏ’s President and CEO, commented that “We are pleased to enter into this partnership with Propagenix, which will enable us to offer an important tool to the scientific community. We expect EpiXâ„¢ to offer unparalleled performance generating epithelial cells useful for countless downstream applications.â€
“Propagenix is excited to partner with ºÚÁÏ³Ô¹Ï to bring EpiXâ„¢ technology to the global research marketâ€, stated Dr. Brian Pollok, Propagenix’s President and CEO. “Their expertise and dedication in supporting the stem cell research community with unique technologies was a deciding factor in our working with ºÚÁϳԹÏ.â€
Contact - ºÚÁϳԹÏ
Benjamin Thiede, Sr. Business Development Officer
benjamin.thiede@stemcell.com
Contact – Propagenix, Inc.
Brian Pollok, President and CEO
brian.pollok@propagenix.com
About ºÚÁϳԹÏ
As Scientists Helping Scientists, ºÚÁÏ³Ô¹Ï is committed to providing high-quality cell culture media, cell isolation products, accessory reagents and services for life science research. Driven by science and a passion for quality, ºÚÁÏ³Ô¹Ï offers over 2500 products designed to support the basic to translational research continuum. Visit www.stemcell.com.
About Propagenix
Propagenix is a preclinical-stage regenerative medicine company applying its unique and proprietary technologies to internal and partnered cell therapy programs. Propagenix’s technology platform has proven ability for propagating tissue-resident epithelial stem cells of diverse tissue origins with unparalleled production efficiency, reliable safety, and predictable in vivo functionality. In addition to cell therapeutics, Propagenix’s technology addresses key bottlenecks in using primary cell models for drug discovery and toxicology, as well as creating new possibilities for use of patient-specific samples for precision medicine applications in oncology and respiratory disease. Visit .
Latest ºÚÁÏ³Ô¹Ï News
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to ºÚÁÏ³Ô¹Ï Canada Inc. and its subsidiaries and affiliates (“ºÚÁϳԹÏâ€) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
